174 related articles for article (PubMed ID: 31133363)
1. Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World.
Karim S; Xu Y; Kong S; Abdel-Rahman O; Quan ML; Cheung WY
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):e160-e166. PubMed ID: 31133363
[TBL] [Abstract][Full Text] [Related]
2. Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials.
Batra A; Kong S; Cheung WY
Clin Colorectal Cancer; 2020 Dec; 19(4):e226-e234. PubMed ID: 32636076
[TBL] [Abstract][Full Text] [Related]
3. Eligibility of real-world patients with metastatic breast cancer for clinical trials.
Batra A; Kong S; Cheung WY
Breast; 2020 Dec; 54():171-178. PubMed ID: 33120082
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.
Kawachi H; Fujimoto D; Morimoto T; Ito M; Teraoka S; Sato Y; Nagata K; Nakagawa A; Otsuka K; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e721-e734. PubMed ID: 29934133
[TBL] [Abstract][Full Text] [Related]
6. Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials.
Kaur M; Frahm F; Lu Y; Ascha MS; Guadamuz JS; Dotan E; Gottesman AS; Leybovich BC; Sondhi A; Zhao Y; Meropol NJ; Royce TJ
NEJM Evid; 2024 Apr; 3(4):EVIDoa2300236. PubMed ID: 38771994
[TBL] [Abstract][Full Text] [Related]
7. Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?
Al-Baimani K; Jonker H; Zhang T; Goss GD; Laurie SA; Nicholas G; Wheatley-Price P
Curr Oncol; 2018 Aug; 25(4):e291-e297. PubMed ID: 30111974
[TBL] [Abstract][Full Text] [Related]
8. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.
Marschner N; Staehler M; Müller L; Nusch A; Harde J; Koska M; Jänicke M; Goebell PJ;
Clin Genitourin Cancer; 2017 Apr; 15(2):e209-e215. PubMed ID: 27720164
[TBL] [Abstract][Full Text] [Related]
9. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility.
Fujimoto D; Morimoto T; Tamiya M; Hata A; Matsumoto H; Nakamura A; Yokoyama T; Taniguchi Y; Uchida J; Sato Y; Yokoi T; Tanaka H; Furuya N; Masuda T; Sakata Y; Miyauchi E; Hara S; Saito G; Miura S; Kanazu M; Yamamoto N; Akamatsu H
JAMA Netw Open; 2023 Feb; 6(2):e230698. PubMed ID: 36826813
[TBL] [Abstract][Full Text] [Related]
11. Factors that influence the eligibility of cases for inclusion in clinical trials. The Lung Cancer Chemotherapy Study Group of the Japan Clinical Oncology Group.
Kasai T; Ohe Y; Nishio K; Kunitoh H; Tamura T; Sekine I; Kubota K; Yamamoto N; Nakamura Y; Shinkai T; Kodama T; Saijo N
Jpn J Clin Oncol; 1998 Mar; 28(3):214-21. PubMed ID: 9614446
[TBL] [Abstract][Full Text] [Related]
12. Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting.
Sam D; Gresham G; Abdel-Rahman O; Cheung WY
Med Oncol; 2018 Jun; 35(7):110. PubMed ID: 29915956
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).
Griesinger F; Sebastian M; Brueckl WM; Hummel HD; Jaeschke B; Kern J; Wesseler C; Jänicke M; Fleitz A; Zacharias S; Hipper A; Groth A; Weichert W; Dörfel S; Petersen V; Schröder J; Wilke J; Eberhardt WEE; Thomas M;
JTO Clin Res Rep; 2024 Apr; 5(4):100626. PubMed ID: 38586301
[TBL] [Abstract][Full Text] [Related]
14. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
Thorac Cancer; 2018 Jun; 9(6):736-744. PubMed ID: 29682899
[TBL] [Abstract][Full Text] [Related]
15. Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey.
Canouï-Poitrine F; Lièvre A; Dayde F; Lopez-Trabada-Ataz D; Baumgaertner I; Dubreuil O; Brunetti F; Coriat R; Maley K; Pernot S; Tournigand C; Hagege M; Aparicio T; Paillaud E; Bastuji-Garin S
Oncologist; 2019 Dec; 24(12):e1351-e1359. PubMed ID: 31324663
[TBL] [Abstract][Full Text] [Related]
16. Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment.
Penberthy L; Brown R; Wilson-Genderson M; Dahman B; Ginder G; Siminoff LA
Clin Trials; 2012 Dec; 9(6):788-97. PubMed ID: 23033547
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
18. Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-
Harvey RD; Bruinooge SS; Chen L; Garrett-Mayer E; Rhodes W; Stepanski E; Uldrick TS; Ison G; Khozin S; Rubinstein WS; Schenkel C; Miller RS; Komatsoulis GA; Schilsky RL; Kim ES
Clin Cancer Res; 2021 May; 27(9):2430-2434. PubMed ID: 33563634
[TBL] [Abstract][Full Text] [Related]
19. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
[TBL] [Abstract][Full Text] [Related]
20. Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.
Hosoya K; Fujimoto D; Kawachi H; Sato Y; Kogo M; Nagata K; Nakagawa A; Tachikawa R; Hiraoka S; Kokubo M; Tomii K
Cancer Chemother Pharmacol; 2019 Aug; 84(2):275-280. PubMed ID: 31201490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
